Wednesday, April 22nd, 2026: Day OneWednesday, 22 April 2026 - US/Eastern

AI is rewriting the future of clinical innovation—faster, smarter, more precise. But with this incredible computing power comes a new kind of responsibility. This opening keynote challenges leaders to see trust not as a compliance checkbox, but as the currency of progress.

Key Themes:

• Why transparency and accountability are the foundation of credible innovation

• Balancing ambition with ethical stewardship in patient-facing technologies

• How organizations earn—and keep—the world’s trust in the age of AI

Alzheimer’s trials generate massive volumes of biomarker, imaging, and clinical data. AlzheonNexus brings these sources together into one connected analytics environment, enabling teams to interpret disease progression, optimize trial design, and uncover insights that would otherwise remain siloed.

Key Themes:
• Case examples of multimodal biomarker and clinical data integration
• Lessons from building a unified analytics environment for large Alzheimer’s trials
• Applying AI to improve prediction, patient selection, and endpoint interpretation
• How connected data science accelerates decision making across neurodegeneration programs

The regulatory map is evolving fast. This candid dialogue with global regulators and industry veterans examines how agencies are adapting oversight for AI-enabled trials—and what true harmonization might look like.

Key Themes:

• Emerging frameworks from the FDA, EMA, MHRA, and beyond

• Managing cross-border data flow, validation, and privacy requirements

• Preparing for next-generation audits and AI documentation standards

• The path toward mutual recognition and international collaboration

• How sponsors can stay compliant amid rapidly changing expectations

Clinical data only has power when it speaks the same language. This session highlights organizations that have achieved true interoperability—connecting systems like Veeva, Medidata, and in-house tools into a single, living data ecosystem.

Key Themes:

• Case studies on seamless EDC–CTMS–eSource integration

• Lessons learned from unifying legacy platforms with cloud-native solutions

• Building APIs and governance models that keep data flowing, not fragmenting

• How real-time connectivity transforms analytics, oversight, and quality

How leaders turn bold ideas into measurable impact. This session bridges strategy and execution—showing how to make the business case for AI while choosing the smartest path to scale.

Key Themes:

• Building internal momentum through AI councils and cross-functional alignment

• Defining KPIs that matter—recruitment, retention, adherence, cycle time, data lock

• The build–buy–partner dilemma: evaluating cost, readiness, and long-term ROI

• Making innovation make sense to boards, investors, and regulators

Great trials start with the end in mind. This session explores how forward-thinking trial sponsors are linking protocol design, budgeting, and regulatory planning to create seamless data continuity from concept to submission.

Key Themes:

• Designing studies that anticipate downstream data needs

• Aligning protocol, regulatory, and budgeting teams early in the process

• Breaking silos between design, execution, and compliance systems

• How unified data architecture accelerates approvals and reduces re-work

Pipeline decisions no longer need to be made by a slow stage-gate process only using science, commercial and regulatory data. We now have access to AI-driven insight that is rewriting early development strategy—helping organizations say “go” or “no-go” faster, smarter, and with greater confidence.

Key Themes:

• How predictive modeling reduces false positives in Phase I/II studies

• Real-world case study: AI-optimized decision frameworks in action

• Interactive walk-through of a redefined portfolio review process

• Balancing data-driven precision with human judgment in R&D strategy

As clinical trials evolve, placing the patient experience at the center of study design is no longer optional—it’s essential. This session explores how sponsors and sites can better account for the patient journey, from recruitment through participation, by integrating accessibility, health status, and logistical realities into trial planning. It also looks ahead to the growing role of in silico and fully remote trials in reshaping the clinical landscape.

• Understanding the Patient Journey: Consider how factors like transportation, mobility, and overall health impact a patient’s ability to participate in a trial—and how these should inform site selection and protocol design

• Patient-Centered Site Selection and Recruitment: Learn how to choose trial sites based not only on capacity and expertise, but also on proximity to patient populations and their diverse needs. Explore empathetic recruitment strategies that respect patients’ time, health, and personal circumstances—ultimately improving enrollment and retention

• Remote & In Silico Trials: Examine how virtual trials and computer-simulated models can reduce patient burden, expand access, and accelerate timelines—while maintaining scientific rigor

When global scale meets start-up speed—everyone wins. This interactive discussion bridges perspectives from large and emerging organizations to uncover where collaboration creates true value.

Key Themes:

• Comparing AI adoption journeys across organization sizes

• Lessons from both sides: enterprise structure vs. start-up agility

• Identifying partnership models that accelerate innovation and reduce redundancy

• Open exchange on shared roadblocks2, wins, and future opportunities